Tuesday, November 5, 2024
HomeTagsPEACE Phase 3 Study

PEACE Phase 3 Study

Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, shared additional...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics